We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Spanish drugmaker Toskani Pharmaceutical has plans to build a €2.5 million plant in Gambia, which will be the first pharmaceutical manufacturing plant in that country.
Canada's minister of health, Tony Clement, announced that Health Canada and the Public Health Agency of Canada have signed a new formal partnership arrangement with the Joint United Nations Programme on HIV/AIDS (UNAIDS).
The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has issued a Class 2 drug alert informing healthcare professionals that Link Pharmaceuticals is recalling its Pabrinex Intravenous High Potency Injection due to the presence of particulate contamination.
Hong Kong has issued safety warnings in connection with several traditional Chinese medicines contaminated with prescription-only drugs and harmful impurities.
Aida Pharmaceuticals, Inc., one of mainland China's leading pharmaceutical companies, announced that the Company has completed its acquisition of the majority control of Shanghai Qiaer Bio-Technology Co., Ltd.
ShinNippon Biomedical Laboratories' two subsidiaries, Translational Research Ltd. and Bioactis Ltd. have signed general terms of agreement for the licensing and supplying of their patented nasal drug delivery technology in the field of endocrinology to Tokai Pharmaceuticals of Massachusetts, USA.
Novartis India has approached Chennai High Court against the orders of the Patent Controller invalidating the patent claim on Novartis' block buster anti-cancer drug Glivec (Imatinib Mesvlate).
How does a publicly listed corporation lose track of more than $17 million? Australian Pharmaceutical Industries is unable to explain a financial black hole that has sparked a massive profit downgrade and evidently cost its boss his $660,000-a-year job.
Evotec AG announced that CHDI, Inc., a not-for profit organisation pursuing a biotech approach to finding therapies for Huntington Disease, has chosen Evotec as a strategic partner for helping them advance its drug discovery programmes.